Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
6.90
-0.47 (-6.38%)
At close: May 15, 2026, 4:00 PM EDT
7.02
+0.12 (1.74%)
After-hours: May 15, 2026, 7:27 PM EDT
Sagimet Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
426.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 2.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fulcrum Therapeutics | 80.00M |
| ADC Therapeutics | 79.18M |
| vTv Therapeutics | 36.84M |
| Prelude Therapeutics | 16.72M |
| Ovid Therapeutics | 7.12M |
| PureTech Health | 4.66M |
| Ocugen | 4.47M |
| Upstream Bio | 3.32M |
SGMT News
- 3 days ago - Sagimet Biosciences price target lowered to $28 from $37 at Clear Street - TheFly
- 3 days ago - Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - GlobeNewsWire
- 4 days ago - Sagimet Biosciences reports Q1 EPS (33c), consensus (35c) - TheFly
- 4 days ago - Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 5 days ago - Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago - GlobeNewsWire
- 12 days ago - Sagimet Biosciences price target raised to $49 from $28 at Canaccord - TheFly
- 15 days ago - Sagimet Biosciences price target raised to $33 from $28 at Oppenheimer - TheFly
- 16 days ago - Sagimet Biosciences Transcript: Status update - Transcripts